桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2024-032 桂林莱茵生物科技股份有限公司 2023年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议的召开情况 1、会议届次：2023年度股东大会 2、会议召集人：公司第六届董事会，公司第六届董事会第三十一次会议决 议召开本次股东大会。 3、会议召开方式：现场表决与网络投票相结合，股东应选择现场投票、网 络投票中的一种方式，如果同一表决权出现重复投票表决的，以第一次投票表决 结果为准。 4、会议时间及地点： 现场会议的召开时间为2024年5月6日下午15:00，现场会议的召开地点为桂 林市临桂区人民南路19号公司四楼会议室。 网络投票：通过深圳证券交易所交易系统投票的时间为2024年5月6日上午 9:15—9:25，9:30—11:30以及下午13:00—15:00；通过深圳证券交易所互联网投票 系统（http://wltp.cninfo.co ...

Investment Rating - The report maintains a "Buy" rating for the company, with expected EPS of 0.24/0.33/0.47 yuan for 2024-2026 and corresponding P/E ratios of 32/24/17 times [13] Core Viewpoints - The company is a global leader in the plant extraction industry, leveraging R&D, process, and management advantages to build core competitiveness [13] - With the end of the industry's inventory destocking cycle and rising product prices, the company's profitability is expected to improve continuously [13] - The company's globalization strategy is steadily advancing, with overseas revenue reaching 994 million yuan in 2023, a 6% YoY increase [29] - The company initiated a global supply chain layout in 2023, exploring opportunities in Southeast Asia, Central Asia, South America, and Africa to enhance risk resilience [29] Financial Performance - The company's 2023 revenue was 1.494 billion yuan, a 7% YoY increase, with Q4 revenue of 605 million yuan, a 43% YoY increase [34] - Net profit attributable to the parent company in 2023 was 83 million yuan, a 53.8% YoY decrease, but Q4 net profit was 42 million yuan, a 1323% YoY increase [34] - The company's gross margin in 2023 was 24.41%, a 6 percentage point YoY decrease, mainly due to price declines in core plant extraction products and inventory impairment [34] - The company's net profit margin in 2023 was 6.58%, a 7 percentage point YoY decrease, but improved to 8.17% in Q1 2024 [34] Business Segments - The plant extraction business achieved revenue of 1.484 billion yuan in 2023, a 12% YoY increase [34] - Natural sweetener business revenue was 903 million yuan in 2023, a 2% YoY increase, driven by volume growth despite price declines in monk fruit [34] - Tea extract business revenue was 179 million yuan in 2023, a 10% YoY increase, with a gross margin exceeding 30% [34] - Industrial hemp business incurred a loss of 70 million yuan in 2023 due to market clearing, but the company is accelerating capacity release in the hemp vaping sector [34] Future Outlook - The company is expected to achieve revenue of 1.793/2.115/2.453 billion yuan in 2024-2026, with YoY growth rates of 20%/18%/16% [35] - Net profit attributable to the parent company is expected to reach 180/246/347 million yuan in 2024-2026, with YoY growth rates of 117.9%/37%/40.7% [35] - ROE is projected to improve from 2.6% in 2023 to 5.6%/7.8%/11.1% in 2024-2026 [35] Share Repurchase - The company plans to repurchase 1-2 billion yuan worth of shares at a price not exceeding 8.50 yuan per share for equity incentive or employee stock ownership plans [40] - As of March 31, 2024, the company has repurchased 7.9921 million shares, accounting for 1.08% of the total share capital [40]

Financial Performance - The company's revenue for Q1 2024 reached ¥341,215,308.03, representing a 35.07% increase compared to ¥252,624,843.19 in the same period last year[3] - Net profit attributable to shareholders was ¥26,790,064.13, up 34.37% from ¥19,937,378.89 year-on-year[3] - The net profit after deducting non-recurring gains and losses surged by 372.05% to ¥39,570,887.50, compared to ¥8,382,853.49 in the previous year[3] - The company achieved a consolidated revenue of RMB 341.22 million in Q1 2024, representing a year-on-year growth of 35.07%[15] - The net profit attributable to shareholders reached RMB 26.79 million, a year-on-year increase of 34.37%, with a 372.05% growth in net profit after deducting non-recurring gains and losses[15] - In Q1 2024, the company reported a net profit of CNY 27,884,546.77, an increase of 22.8% compared to CNY 22,746,832.35 in Q1 2023[30] - The total revenue from operating activities reached CNY 665,699,925.37, up from CNY 392,343,449.64 in the same period last year, representing a growth of 69.5%[32] - The company's operating profit was CNY 38,694,563.32, compared to CNY 26,222,155.48 in Q1 2023, marking a year-over-year increase of 47.6%[30] - The total comprehensive income for the period was CNY 29,338,961.00, compared to CNY 13,309,904.98 in the same quarter last year, reflecting a growth of 120.5%[31] - The company reported a significant increase in sales revenue from CNY 627,894,881.41 in Q1 2024, compared to CNY 359,879,120.69 in Q1 2023, indicating a growth of 74.5%[32] Cash Flow and Assets - The net cash flow from operating activities increased significantly to ¥15,776,635.33, a 2,956.62% rise from -¥552,283.38 in Q1 2023[3] - The company's cash and cash equivalents increased by 67.16% to ¥218,063,579.63, driven by a substantial rise in sales collections[8] - The company's cash and cash equivalents increased to RMB 218,063,579.63 from RMB 130,453,809.30, reflecting a growth of approximately 67%[25] - The cash flow from operating activities showed a net increase of CNY 15,776,635.33, contrasting with a negative cash flow of CNY -552,283.38 in Q1 2023[32] - The cash and cash equivalents at the end of the period amounted to CNY 110,892,028.16, a slight increase from CNY 110,718,019.51 at the beginning of the period[33] Shareholder Information - As of March 31, 2024, the company repurchased a total of 7,992,071 shares, accounting for 1.08% of the total share capital, with a total transaction amount of RMB 49.96 million[18] - The company plans to use between RMB 100 million and RMB 200 million for share repurchase to enhance investor confidence[17] - The company has implemented a share repurchase plan to support employee stock ownership and incentive programs[17] - The major shareholders include Qin Benjun with a 36.58% stake, and the top ten shareholders hold a significant portion of the company's shares[14] Investments and Agreements - The company signed a new five-year agreement with DSM-Firmenich, with a total contract value of USD 68 million, of which USD 1.41 million has been fulfilled in the current reporting period[19][20] - The company is investing USD 5 million to establish two brand and operation companies in the U.S. for industrial hemp vaporization products, with operations officially commenced[21][22] Operational Metrics - Total assets at the end of Q1 2024 were ¥4,768,230,024.88, reflecting a 3.08% increase from ¥4,625,577,132.96 at the end of the previous year[3] - The company's basic earnings per share rose to ¥0.04, a 33.33% increase from ¥0.03 in the same quarter last year[3] - The weighted average return on equity improved to 0.86%, up from 0.65% year-on-year[3] - The total operating costs for the first quarter of 2024 were RMB 297,588,999.84, up from RMB 241,217,950.90 in the previous year, indicating a 23.5% increase[29] - The inventory balance rose to RMB 1,250,243,019.00, compared to RMB 971,298,948.11 at the beginning of the period, marking a 29% increase[26] - The total liabilities increased to RMB 1,582,572,457.44 from RMB 1,421,120,433.26, showing a growth of approximately 11.4%[27] - The company's equity attributable to shareholders decreased slightly to RMB 3,111,765,600.41 from RMB 3,131,659,215.31[27] - The company incurred financial expenses of CNY 3,459,863.60, down from CNY 4,099,796.18, a decrease of 15.7%[30] - Research and development expenses decreased to CNY 9,659,639.15 from CNY 11,642,233.61, a reduction of 17.0%[30] Fundraising - The company raised a total of RMB 967,999,997.25 from a private placement of 165,470,085 shares at RMB 5.85 per share, with a net amount of RMB 961,109,931.12 after deducting issuance costs[23] - The company has RMB 48,231.42 million of unutilized raised funds, with RMB 48,000.00 million temporarily used to supplement working capital[23] - The company reported cumulative interest income from the raised funds amounting to RMB 14,765,200.00[23]

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2024－031 桂林莱茵生物科技股份有限公司 关于召开 2023 年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）于 2024 年 4 月 10 日 在《中国证券报》《证券时报》《上海证券报》《证券日报》和巨潮资讯网 （www.cninfo.com.cn）刊登了《关于召开 2023 年度股东大会的通知》（公告编 号：2024-026），现根据有关规定，就召开本次股东大会的相关事项再次通知如 下： 一、召开会议的基本情况 （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为 2024 年 5 月 6 日上午 9:15—9：25，9：30—11:30 以及下午 13:00—15:00；通过深圳证券 交易所互联网投票系统（http://wltp.cninfo.com.cn）投票时间为 2024 年 5 月 6 日 上午 9:15 至下午 15:00。 5、会议召开方式：本次股东大会采取现场表决与网络投票 ...

桂林莱茵生物科技股份有限公司 关于控股股东、实际控制人部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）董事会于2024年04 月25日接到控股股东、实际控制人秦本军先生的通知，获悉秦本军先生将其所持 有的部分公司股份办理了质押业务，具体事项如下： 二、股东股份累计质押情况 截至公告披露日，上述股东所持质押股份情况如下： 桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2024-029 | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次质押 | 本次质押 | 占其所 | 占公司 | 情况 | | 情况 | | | 股东 | 持股数量 | 持股比 | 前质押股 | 后质押股 | 持股份 | 总股本 | 已质押股 | 占已质 | 未质押股 | 占未质 | | 名称 | （万股） | 例（% ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2024－028 桂林莱茵生物科技股份有限公司 关于举办2023年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）2023 年度报告已于 2024 年 04 月 10 日披露，为使广大投资者进一步了解公司 2023 年度经营情况， 公司定于 2024 年 04 月 29 日（星期一）在价值在线（www.ir-online.cn）召开 2023 年度网上业绩说明会，将针对经营业绩等投资者关心的问题与广大投资者进行在 线沟通交流。现将有关事项公告如下： 一、业绩说明会的安排 为充分尊重投资者、提升公司与投资者之间的交流效率及针对性，现就公司 2023 年度业绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建 议。投资者可于 2024 年 04 月 26 日前通过上述链接进行会前提问，公司将通过 本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行回答。 本次业绩说明会召开后，投资者可以通过价值 ...

Dividend Distribution - The company plans to distribute a cash dividend of 2 CNY per 10 shares to all shareholders, based on a total share capital of 741,986,825 shares, excluding shares in the repurchase account[5]. - The company has a total of 741,986,825 shares outstanding, which will be the basis for the dividend distribution[5]. - In 2022, the company distributed cash dividends of RMB 74,208,242.50, at a rate of RMB 1.00 per 10 shares, based on a total share capital of 742,082,425 shares[200]. Financial Performance - The company's operating revenue for 2023 was ¥1,493,929,546.69, representing a 6.65% increase compared to ¥1,400,737,343.44 in 2022[22]. - The net profit attributable to shareholders decreased by 53.84% to ¥82,510,982.99 from ¥178,745,385.35 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 86.17% to ¥20,615,597.65 from ¥149,067,554.85 in 2022[22]. - The net cash flow from operating activities improved significantly, reaching ¥116,589,971.61, compared to a negative cash flow of ¥258,422,111.78 in 2022, marking a 145.12% increase[22]. - The total assets at the end of 2023 were ¥4,625,577,132.96, a 3.82% increase from ¥4,455,360,858.16 at the end of 2022[22]. - The net assets attributable to shareholders increased by 2.18% to ¥3,131,659,215.31 from ¥3,064,751,877.97 in 2022[22]. - The company achieved total revenue of CNY 149,392.95 million, a year-on-year increase of 6.65%, with plant extraction business revenue reaching CNY 148,410.45 million, up 12.27% due to market demand recovery in Q4[73]. - Net profit attributable to shareholders was CNY 8,251.10 million, a decrease of 53.84%, primarily due to a decline in market prices of core plant extraction products and increased expenses[73]. Market Trends and Industry Insights - In 2023, China's plant extract industry experienced its first negative growth in recent years, with total export value declining to $3.32 billion, a decrease of 6% year-on-year[38]. - The export value of non-essential oil plant extracts was $2.91 billion, down 6.2% year-on-year, indicating a contraction in demand from traditional markets like the US and Europe[38]. - The ASEAN market showed significant growth, with non-essential oil plant extract exports reaching $340 million in 2023, highlighting a shift in export focus[39]. - The plant extraction industry accounted for 50% of China's traditional Chinese medicine foreign trade, with plant extracts making up 60% of the export share, underscoring its importance[36]. - The plant extraction industry is expected to maintain a strong growth trend in 2024, driven by consumption upgrades and health demands, with a projected increase in market scale[129]. - The global dietary supplement market reached $176.17 billion in 2022, expected to approach $200 billion by 2025, indicating strong growth potential[130]. - The natural cosmetics market is projected to reach $54.4 billion by 2027, with China's functional skincare market expected to grow to ¥418 billion by 2026[130]. - The global plant extract market is expected to grow from $18.09 billion in 2020 to $32.46 billion by 2027, with a CAGR of 7.9%[130]. Research and Development - The company is focusing on R&D and innovation to maintain a competitive edge in a market characterized by homogenization and increasing consumer demand for personalized health solutions[37]. - The company has developed over 300 standardized plant extraction products, including monk fruit extract, stevia extract, industrial hemp extract, and tea extract, serving various sectors such as food, beverage, medicine, and cosmetics[48]. - The company has established a Plant Science Innovation Center focused on the R&D and cultivation of high-quality monk fruit and stevia seedlings, and set up a Health Product R&D Center in Shanghai for application research of plant extracts in consumer products[62]. - The company has formed strategic partnerships with several universities and research institutions, including Hunan Agricultural University and Jiangnan University, to enhance R&D capabilities and talent cultivation[63]. - The company has implemented a "company + cooperative + farmer" model for raw material procurement, ensuring stable supply and quality of stevia and monk fruit[70]. - The company is developing a proprietary monk fruit breeding system to ensure a sustainable supply of high-quality raw materials[99]. - The company's R&D investment increased by 10.00% to ¥55,950,286.47 in 2023, representing 3.75% of total revenue[100]. Corporate Governance - The governance structure includes a board of 7 members, with 3 independent directors, ensuring compliance with legal requirements and promoting effective decision-making[171]. - The company has established a robust internal control system to enhance operational efficiency and governance standards[170]. - The company is committed to maintaining independence from its controlling shareholder, ensuring autonomous business operations[170]. - The board has established specialized committees, including an audit committee, to provide professional oversight and recommendations[172]. - The company has a fully independent business system, focusing on the research, production, and sales of natural health products, with no competition from its controlling shareholders[176]. - The company has established an independent financial department and accounting system, ensuring no shared bank accounts with controlling shareholders[175]. Employee Development and Training - The total number of employees at the end of the reporting period is 1,146, with 775 in the parent company and 371 in major subsidiaries[195]. - The company organized 62 training sessions in 2023, totaling 15,517 hours of training, resulting in an average of 22 hours of training per employee[197]. - The company developed over 60 internal training courses in 2023 to enhance employee skills and promote internal talent development[198]. - The company adheres to a performance evaluation system to determine salary levels based on job nature and regular assessments[196]. - The company plans to continuously improve performance evaluation standards and attract and retain talented individuals[196]. Strategic Initiatives - The company plans to enhance its market expansion efforts and product development in response to the recovering market demand[28]. - The company aims to strengthen its global supply chain through investments, collaborations, and renovations to meet diverse customer needs[128]. - The company is exploring strategic acquisitions to enhance its product portfolio and market reach, with a budget of $30 million allocated for potential deals[166]. - The company plans to accelerate the development of new consumer products in the health sector, including low-sugar food and beverages, while enhancing its sales channels and self-operated platforms[150]. - The company aims to enhance competitiveness by increasing investment in formula applications and collaborating with research institutions for product optimization[134]. Risk Management - The company acknowledges potential risks from regulatory changes in food safety and industrial hemp, and plans to adapt its strategies accordingly to maintain competitiveness[156]. - The company is focused on mitigating financial risks associated with foreign exchange fluctuations and increasing accounts receivable and inventory levels due to business growth[162]. - Management risks are heightened due to business expansion, prompting the company to invest in training and digital capabilities for its management team[163].

桂林菜茵生物科技股份有限公司 二〇二三年度 审计报告 致同会计师事务所(特殊普通合伙) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn/ 报告编码:京2 108 | 09000000 WANDA SEE WEEK NNNDSO IN MERIC DEN DEADE 葡萄台 and and | .. | | --- | | 审计报告 | 1-5 | | --- | --- | | 合并及公司资产负债表 | 1-2 | | 合并及公司利润表 | 3 | | 合并及公司现金流量表 | 4 | | 合并及公司股东权益变动表 | 5-8 | | 财务报表附注 | 9-100 | 905-200 manus 1450 Ca parti 审计报告 致同审字(2024)第 450A007399 号 桂林莱茵生物科技股份有限公司全体股东: 一、审计意见 我们审计了桂林莱茵生物科技股份有限公司(以下简称莱茵生物公司) 财务报表,包括 2023年12月 31日的合并及公司资产负债表,2023年度的合 并及公司利润表、合并及公司现金流量表、合并及公司股东权益变动表以及 相关财务报 ...

证券代码：002166 证券简称：莱茵生物 公告编号：2024-025 桂林莱茵生物科技股份有限公司 2023年度募集资金存放与实际使用情况 专项报告 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要 求（2022年修订）》和《深圳证券交易所上市公司自律监管指引第1号——主板 上市公司规范运作》有关规定，桂林莱茵生物科技股份有限公司（以下简称"本 公司"）现将公司2023年度募集资金存放与实际使用情况说明如下： 一、募集资金的基本情况 （一）实际募集资金金额、资金到位时间 桂林莱茵生物科技股份有限公司 2、本年度使用金额及当期余额 2023年度，本公司募集资金使用情况为： 以募集资金直接投入募投项目38,977.65万元。截至2023年12月31日，募集资 金累计投入43,214.98万元，尚未使用的募集资金金额为54,315.98万元（其中闲置 1 经中国证券监督管理委员会证监许可[2021]2843号文《关于核准桂林莱茵生 物科技股份有限公司非公开发行股票的批复》核准，并经深圳证券交易所同意， 公司非公开发行股票在深圳证券交易所上市交易。本次非公开发行人民币普通股 （A股）165,470 ...

内部控制审计报告 致同会计师事务所 (特殊普通合伙) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mn.cngr.cn/） 进行查报 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://accy.no.jp/ "进行查测: 324WK5.0V7N0 桂林莱茵生物科技股份有限公司 二〇二三年度 The Will 017 BEATH BOOK HOW 网站网 E 200000 Carol 骗局会 100万元 T No 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性 发表审计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 hornton 内部控制审计报告 致同审字(2024)第 450A007412 号 桂林莱茵生物科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求, 我们审计了桂林莱茵生物科技股份有限公司(以下简称莱茵生物公司)2023 年 12月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企 ...